Boehringer Ingelheim signs two-year license deal with Qlucore

November 21, 2021

Boehringer Ingelheim has ordered licenses from Qlucore at a value of approximately 142,000 EURO for the use of Qlucore Omics Explorer for two years. Boehringer Ingelheim is a leading pharmaceutical company with focus on research and development, with several locations around the world. Boehringer Ingelheim is an existing Qlucore customer, and this license is for global use of Qlucore’s software.

Qlucore Omics Explorer is software for research applications within the pharma, biotech and academic communities. The user is provided with functionality including fast, interactive visualization combined with smart calculations to discover important information and findings in large, and often extremely large, data sets. Qlucore software is used by scientists in more than 200 organizations and more than 25 countries, and there are more than 1000 scientific articles referring to Qlucore Omics Explorer software.

“We are delighted that Boehringer Ingelheim has again decided to order Qlucore Omics Explorer licenses from us for use in its research and development.” says Carl-Johan Ivarsson, Qlucore CEO.